ULK3 and chronic myelogenous leukemia, BCR-ABL1 positive: Two ULK3-targeting drugs were identified, one of which has gained approval for the treatment of chronic myeloid leukemia, while another has demonstrated potential in mitigating cardiac ischemia/reperfusion injury.